One of the more deleterious features of this site, and others like it, is that a small number of non-medics with their own subjective experiences promote guidance. If something appears to work for them, which is to be welcomed, it is promoted as if this is a universal truth. Sometimes, perhaps even often, this flies in the face of current established and scientifically backed protocols. Of course, personal opinions and experiences are a valuable resource, and may feed into scientific understanding, but they do not substitute for empirical peer-reviewed research. It is also important that we monitor latest scientific research. In this regard, it is perhaps regrettable that KayXo has referred to research conducted as long ago as 1991 and 2003. Many more recent studies have moved along the scientific understanding of transgender treatment.
Both the World Professional Association for Transgender Health (WPATH) and the Endocrine Society have created transgender-specific guidelines to help serve as a framework for providers caring for gender minority patients. These guidelines are mostly based on clinical experience from experts in the field. Guidelines for hormone therapy in transgender men are mostly extrapolations from recommendations that currently exist for the treatment of hypogonadal natal men and estrogen therapy for transgender women is loosely based on treatments used for postmenopausal women. It is important to note that, in many cases, MtF patients are reliant on non-specific treatment studies.
Therefore, let's be clear about this. Current WPATH and scientific papers do, indeed, suggest that Estrogen, through a feedback loop, does suppress testosterone. However:
"Hormone therapy for transgender women is intended to feminize patients by changing fat distribution, inducing breast formation, and reducing male pattern hair growth Estrogens are the mainstay therapy for trans female patients. Through a negative feedback loop, exogenous therapy suppresses gonadotropin secretion from the pituitary gland, leading to a reduction in androgen production.
Estrogen alone is often not enough to achieve desirable androgen suppression, and adjunctive anti-androgenic therapy is also usually necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182227/This backed by a scientific study and presented to the Endocrine Society in their Chicago conference 2014.
"Simply giving estrogen to male-to-female transgender patients won't completely suppress testosterone levels, researchers reported here." This study by Dr Leiniung is, however, a single study and presents conflicting advice, so we need to be wary until further research has been conducted."
https://www.medpagetoday.com/meetingcoverage/endo/46497WPATH and the Endocrine Society guidelines are quite clear about the protocols regarding anti androgens. Most importantly of all,
anti androgens permit lower doses of estrogen, which is beneficial for health reasons:
"Suppression of testosterone production and blocking of its effects contributes to the suppression / minimization of male secondary sexual characteristics. Unfortunately many of these characteristics are permanent upon completion of natal puberty and are irreversible.
Androgen blockers allow the use of lower estradiol dosing, in contrast to the supraphysiologic estrogen levels (and associated risks) previously used to affect pituitary gonadotropin suppression."
http://transhealth.ucsf.edu/trans?page=guidelines-feminizing-therapyThe bottom line here to everyone who sees this is
please go and seek professional medical help. Do not self-prescribe. Have your blood levels regularly checked and be very wary about something diverging from current WPATH guidelines. At the least, ensure you discuss this thoroughly with a properly trained medical professional.
See also:
Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000;85:2913-21. 10.1210/jcem.85.8.6710
Dittrich R, Binder H, Cupisti S, et al. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2005;113:586-92. 10.1055/s-2005-865900